Practical Management, Emerging Evidence and Technologic Advances in Small Cell Lung Cancer

Practical Management, Emerging Evidence and Technologic Advances in Small Cell Lung Cancer is organized by American Society for Radiation Oncology (ASTRO).

Course opens: 01/11/2018
Course expires: 01/10/2021

Accreditation:
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Description:
This session will discuss current evidence and emerging treatment options in the management of SCLC. An overview of SCLC will be provided including definitions, staging, epidemiology, pathology and other general considerations. Pertinent controversies in limited stage SCLC, such as the timing of radiation, commonly delivered dose fractionations and the use of prophylactic cranial irradiation will be discussed. In extensive stage SCLC, the pros and cons of consolidative thoracic radiation as well as prophylactic cranial irradiation will be highlighted. Finally, the role of emerging radiation treatments, such as hippocampal sparing prophylactic cranial irradiation and stereotactic ablative radiotherapy will be considered.

Learning Objectives:
After this session, attendees should be able to:
• Describe the evidence for the curative, palliative and prophylactic role of radiation in small cell lung cancer.
• Define the role of advanced radiation techniques such as hippocampal-sparing prophylactic cranial irradiation and stereotactic ablative radiotherapy in small cell lung cancer.